Evotec AG and Ono Pharmaceutical Tighten Collaborations
Evotec AG (Hamburg, Germany) has announced it is extending the protease collaboration it forged with Ono Pharmaceutical (Osaka, Japan) back in March 2008 and is entering into a new discovery agreement with the international drug development company. The new agreement targets an ion channel-ion channels are said to be implicated in cardiovascular, neurological, urological, metabolic, andinflammatory diseases.
Under the new agreement, Evotec will receive research funding for 18 months along with success-based milestones based on progress. Ono, meanwhile, is given worldwide rights to develop and market a product containing the compound discovered.
“Since...the existing collaboration with Evotec targeting a protease has progressed as planned, we are now pleased to enter into a new drug discovery agreement on an ion channel with Evotec utilizing their proprietary drug discovery platform," said Ono's Kazuhito Kawabata, PhD, Managing Director, Research Headquarters. "We anticipate the collaboration will result in identifying a novel drug candidate with a high potential.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
